Biological, Genetic and Environmental Involved in the Complications of Sickle Cell Disease

Free University of Brussels (ULB)

Status: Enrolling

Conditions: Sickle Cell Disease

Treatments: Genetic: sickle cell syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT04205123

P2014/251

Details and patient eligibility

About

The objective of the study is to refine our knowledge on the physiopathology of the symptoms and the complications for the patients affected by a drepanocytic syndrome.

The establishment of risk factors and indicators of severity will allow to target better the patients requiring an adequate strategy in order to prevent the installation of some complications or to limit their worsening.

Full description

Some additional tubes will be taken during the usual control of blood test of the drepanocytic patient. A sample of urine will be also asked. Tubes, after pre-treatment, will be sent to Erasme hospital.

A series ob biological but also genetic parameters, both at asymptomatic patients and those in aigüe phase of the disease, can be measured either immediately or a little time after the prelevement.

In this way, we can study numerous domains linked to the physiopathology of the drepanocytose (hémolyse, vaso-occlusion, rheology, factors modulators of the clinical expression). The surplus of the collection could be used for other researchs. It's in this context that we also wish to constitute a biobank of serum, plasma and urine for these drepanocytic patients by surplus of taken material.

The study is realized within the framework of an academic collaboration between institutions. The bank of takings will be located in the reference center of the pathologies of the Red Blood Cell (laboratory of medical chemistry of the erasme hospital).

Enrollment: 200 estimated patients

Sex: All

Ages: 17+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients 18 years or older with sickle cell syndrome
• Signing an inform consent form after validation on it by the Ethics Committees of the participating centers.

Exclusion criteria

• Any pathology concomitant risk of nephropathy
• Severe CVO within the month preceding the sampling
• Transfusions within 3 months prior to sampling
• Pregnant patient or within 3 months post- accouhcement

Trial design

200 participants in 1 patient group

sickle cell syndrome

Description:

Inclusions of sickle cell patients aged over 17 years followed regularly in the participating centers.

Treatment:

Genetic: sickle cell syndrome